Literature DB >> 27900017

SIX1 is overexpressed in endometrial carcinoma and promotes the malignant behavior of cancer cells through ERK and AKT signaling.

Xiaochuan Xin1, Yue Li1, Xianghong Yang1.   

Abstract

The sineoculis homeobox homolog 1 (SIX1) protein has been found to be important for cancer progression. However, its biological role in human endometrial carcinomas remains unexplored. The potential mechanism of SIX1-induced cancer progression remains unclear. In the present study, SIX1 protein expression was examined in 84 cases of endometrial carcinoma tissues using immunohistochemisty, and SIX1 was found to be overexpressed in 51.1% (43/84) of cervical cancer cells. Small interfering RNA (siRNA) knockdown of SIX1 was also performed in Ishikawa cells with high endogenous SIX1 expression, and SIX1 was overexpressed in the HEC1B cell line with low endogenous expression. SIX1 overexpression promoted cell growth rate and colony formation ability, whereas SIX1 depletion inhibited cell growth and colony formation. Further analysis showed that SIX1 knockdown downregulated, and SIX1 overexpression upregulated, cyclin D1, cyclin E, phosphorylated (p-)extracellular signal-regulated kinase (ERK), and p-protein kinase B (AKT) expression. The ERK inhibitor, U0126, and AKT inhibitor treatments blocked the effect of SIX1 on proliferation. In conclusion, the present study found that SIX1 overexpression promotes cancer cell growth in endometrial carcinoma, possibly through ERK- and AKT-mediated pathways.

Entities:  

Keywords:  endometrial carcinoma; extracellular signal-regulated kinase; proliferation; protein kinase B; sineoculis homeobox homolog 1

Year:  2016        PMID: 27900017      PMCID: PMC5103964          DOI: 10.3892/ol.2016.5098

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Quantification of protein concentration by the Bradford method in the presence of pharmaceutical polymers.

Authors:  Nils Carlsson; Annika Borde; Sebastian Wölfel; Björn Kerman; Anette Larsson
Journal:  Anal Biochem       Date:  2010-12-22       Impact factor: 3.365

3.  Bcl-2 expression and prognosis of patients with endometrial carcinoma.

Authors:  N Sakuragi; T Ohkouchi; H Hareyama; K Ikeda; H Watari; T Fujimoto; M Kuwabara; R Yamamoto; T Sagawa; T Fujino; S Fujimoto
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

4.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

5.  Gene amplification is a mechanism of Six1 overexpression in breast cancer.

Authors:  Kelly J Reichenberger; Ricardo D Coletta; Aline P Schulte; Marileila Varella-Garcia; Heide L Ford
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

6.  Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer.

Authors:  Jason D Wright; William M Burke; Elizabeth T Wilde; Sharyn N Lewin; Abigail S Charles; Jin Hee Kim; Noah Goldman; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

Review 7.  Revised FIGO staging system for cancer of the ovary, fallopian tube, and peritoneum: important implications for radiologists.

Authors:  Tsukasa Saida; Yumiko Oishi Tanaka; Koji Matsumoto; Toyomi Satoh; Hiroyuki Yoshikawa; Manabu Minami
Journal:  Jpn J Radiol       Date:  2015-12-22       Impact factor: 2.374

8.  Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.

Authors:  Kian Behbakht; Lubna Qamar; Carrie S Aldridge; Ricardo D Coletta; Susan A Davidson; Andrew Thorburn; Heide L Ford
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

9.  Significance of histologic tumor grade in rectal cancer treated with preoperative chemoradiotherapy followed by curative surgery: A multi-institutional retrospective study.

Authors:  Jin Ho Song; Sung Hwan Kim; Jong Hoon Lee; Hyeon Min Cho; Dae Yong Kim; Tae Hyun Kim; Sun Young Kim; Ji Yeon Baek; Jae Hwan Oh; Taek Keun Nam; Mee Sun Yoon; Jae Uk Jeong; Kyubo Kim; Eui Kyu Chie; Hong Seok Jang; Jae Sung Kim; Jin Hee Kim; Ki Mun Kang
Journal:  Radiother Oncol       Date:  2016-01-04       Impact factor: 6.280

10.  Defining a role for the homeoprotein Six1 in EMT and mammary tumorigenesis.

Authors:  Derek C Radisky
Journal:  J Clin Invest       Date:  2009-08-24       Impact factor: 14.808

View more
  7 in total

1.  MicroRNA-23a inhibits endometrial cancer cell development by targeting SIX1.

Authors:  Hong-Lin Li; Jun-Jie Sun; Hui Ma; Shen-Jia Liu; Na Li; Su-Jie Guo; Yang Shi; Yan-Ying Xu; Zhi-Ying Qi; Yu-Quan Wang; Fang Wang; Rui-Meng Guo; Dong Liu; Feng-Xia Xue
Journal:  Oncol Lett       Date:  2019-07-31       Impact factor: 2.967

2.  SIX1 Regulates Aberrant Endometrial Epithelial Cell Differentiation and Cancer Latency Following Developmental Estrogenic Chemical Exposure.

Authors:  Alisa A Suen; Wendy N Jefferson; Charles E Wood; Carmen J Williams
Journal:  Mol Cancer Res       Date:  2019-10-09       Impact factor: 5.852

3.  Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer.

Authors:  Zitong Zhao; Lin Li; Peina Du; Liying Ma; Weimin Zhang; Leilei Zheng; Bo Lan; Bailin Zhang; Fei Ma; Bo Xu; Qimin Zhan; Yongmei Song
Journal:  Theranostics       Date:  2019-02-20       Impact factor: 11.556

4.  Identification of EMT-Related Gene Signatures to Predict the Prognosis of Patients With Endometrial Cancer.

Authors:  Luya Cai; Chuan Hu; Shanshan Yu; Lixiao Liu; Jinduo Zhao; Ye Zhao; Fan Lin; Xuedan Du; Qiongjie Yu; Qinqin Xiao
Journal:  Front Genet       Date:  2020-12-02       Impact factor: 4.599

5.  SPOCK1/SIX1axis promotes breast cancer progression by activating AKT/mTOR signaling.

Authors:  Ming Xu; Xianglan Zhang; Songnan Zhang; Junjie Piao; Yang Yang; Xinyue Wang; Zhenhua Lin
Journal:  Aging (Albany NY)       Date:  2020-12-03       Impact factor: 5.682

6.  microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function.

Authors:  Zhuo Yang; ZiYi Feng; JiaHui Gu; XinHui Li; QianZhe Dong; KuiRan Liu; Yan Li; Ling OuYang
Journal:  Oncotarget       Date:  2017-09-15

7.  MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.

Authors:  Guangyong Chen; Zhuo Chen; Hang Zhao
Journal:  J Cell Mol Med       Date:  2020-03-27       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.